FDA ex­pect­ed to de­cide on As­traZeneca's self-ad­min­is­tered flu vac­cine next quar­ter

If all goes well at the FDA, As­traZeneca hopes to roll out the US’ first self-ad­min­is­tered flu vac­cine ahead of the next cold and flu sea­son, the com­pa­ny an­nounced on Tues­day.

As­traZeneca’s Flu­Mist Quadri­va­lent nasal spray was ap­proved rough­ly two decades ago for ad­min­is­tra­tion by a health­care pro­fes­sion­al. But if reg­u­la­tors OK As­traZeneca’s lat­est ap­pli­ca­tion, el­i­gi­ble peo­ple would be able to re­ceive the vac­cine by mail and ad­min­is­ter it them­selves or to some­one in their care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER